Literature DB >> 8536277

Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro.

K Pryor1, P Stricker, P Russell, D Golovsky, R Penny.   

Abstract

Direct inhibitory effects of bacillus Calmette-Guérin (BCG) and interferon alpha 2b (IFN alpha 2b) on six human bladder carcinoma cell lines, UCRU-BL-13, UCRU-BL-17, UCRU-BL-28, 5637, T24 and J82, were studied using an in vitro proliferation assay. Effects on proliferation following exposure to BCG or IFN alpha 2b were analysed by [3H]thymidine incorporation over 7 days. BCG had an antiproliferative effect on all bladder lines, while sensitivity to IFN alpha 2b varied greatly, being as remarkably low as 1 U/ml for some lines. The antiproliferative effect was greatest when cells were exposed continuously to either agent, but was still evident with a limited exposure. When clinical concentrations were simulated in vitro, BCG+IFN alpha 2b was more effective than BCG alone and as effective as a double BCG concentration. We conclude that, in addition to their immunomodulatory effects, BCG and IFN alpha 2b directly inhibit the proliferation of human bladder cancer cells, and often at extremely low concentrations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536277     DOI: 10.1007/bf01517219

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

Review 1.  The interferon system. A bird's eye view of its biochemistry.

Authors:  G C Sen; P Lengyel
Journal:  J Biol Chem       Date:  1992-03-15       Impact factor: 5.157

2.  Internalization of bacille Calmette-Guerin by bladder tumor cells.

Authors:  M J Becich; S Carroll; T L Ratliff
Journal:  J Urol       Date:  1991-06       Impact factor: 7.450

3.  Interferon receptors on the surface of interferon-sensitive and interferon-resistant urothelial carcinomas.

Authors:  J W Grups; F C Bange
Journal:  Urol Res       Date:  1990

4.  Antiproliferative effects of interferons against human bladder carcinoma cell lines in vitro.

Authors:  J W Grups; H G Frohmüller
Journal:  Urol Int       Date:  1988       Impact factor: 2.089

5.  Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression.

Authors:  U Ucer; H Bartsch; P Scheurich; K Pfizenmaier
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

6.  Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.

Authors:  J Bubeník; M Baresová; V Viklický; J Jakoubková; H Sainerová; J Donner
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

7.  The inhibitory effects of interferon gamma on the growth of bladder cancer cells.

Authors:  S J Hawkyard; A M Jackson; K James; S Prescott; J F Smyth; G D Chisholm
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

8.  Noncycling tumor cells are sensitive targets for the antiproliferative activity of human interferon.

Authors:  J S Horoszewicz; S S Leong; W A Carter
Journal:  Science       Date:  1979-11-30       Impact factor: 47.728

9.  Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells.

Authors:  H Akaza; A Iwasaki; M Ohtani; N Ikeda; K Niijima; I Toida; K Koiso
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

Review 10.  Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy.

Authors:  F M Torti; B L Lum
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

View more
  9 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.

Authors:  Y Luo; X Chen; R Han; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 3.  Medical management of patients with refractory carcinoma in situ of the bladder.

Authors:  J C Kim; G D Steinberg
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.

Authors:  Y Luo; A Szilvasi; X Chen; W C DeWolf; M A O'Donnell
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

5.  Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha.

Authors:  J-L Yang; X-J Qu; P J Russell; D Goldstein
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

6.  BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis.

Authors:  Katja Schwarzer; Martin Foerster; Thomas Steiner; Inge-Marie Hermann; Eberhard Straube
Journal:  Cancer Cell Int       Date:  2010-06-29       Impact factor: 5.722

Review 7.  Combination of BCG and interferon intravesical immunotherapy: an update.

Authors:  Kenneth G Nepple; Howard A Aubert; Matthew R Braasch; Michael A O'Donnell
Journal:  World J Urol       Date:  2009-05-29       Impact factor: 4.226

8.  BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking.

Authors:  Fanghong Chen; Guangjian Zhang; Yoshiki Iwamoto; William A See
Journal:  BMC Urol       Date:  2005-05-12       Impact factor: 2.264

9.  Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells.

Authors:  M C Filion; P Lépicier; A Morales; N C Phillips
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.